Xcout Intel
Latigo Biotherapeutics
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Subscribe to see Latigo Biotherapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Latigo Biotherapeutics at a glance
Latigo Biotherapeutics is a biotech company headquartered in Thousand Oak, United States. It is publicly listed (LTGO) with a market capitalisation of $1.2B. Xcout tracks 24 named people at Latigo Biotherapeutics, including Nima Farzan (CEO, President & Director).
Latigo Biotherapeutics leadership
- Nima FarzanCEO, President & Director
- Neha KrishnamohanChief Business Officer & CFO
- Tim LugoChief Financial Officer
- Neil Kumar SinglaChief Medical Officer
- Bryan MoyerSenior Vice President of Discovery
- Julia ChapmanSenior Vice President of Operations
18 more named people on record for Latigo Biotherapeutics, with roles, board committees and tenure — see the full roster →
Recent Latigo Biotherapeutics news
- IPOLatigo Biotherapeutics, Inc. Common Stock IPO on NASDAQ
- IPOIPO registration (S-1)
- IPOBiotech Sets IPO Terms Behind Non-Opioid Pain Pipeline
- IPOIPO registration (S-1)
7 corporate events on record, with sources — see the full timeline →
Investors
Latigo Biotherapeutics competitors
A few of Latigo Biotherapeutics's closest competitors — see the full list of competitors and alternatives →
Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, non-opioid products for pain management.
Bexson Biomedical is a US-based biopharmaceutical company situated in Santa Barbara, California, focused on the research and development of non-opioid therapeutics and drug delivery systems.
Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel non-opioid therapeutics for the treatment of chronic pain and painful conditions.
Amalgent Therapeutics develops fixed-dose combination therapies that pair opioids with dopamine-modulating adjuvants to provide safe pain management. The company's lead program, AMGT-0220, is designed to reduce required opioid doses, mitigate tolerance development, and lower reward signaling to help patients recover without the risks of conventional opioid treatments.
TigaTx is a Boston-based biotechnology company founded in 2018 that is developing a pipeline of therapies targeting various cancer types and infectious diseases.
Soteria Biotherapeutics, Inc. is a biopharmaceutical company founded in 2018 and headquartered in San Francisco, California, specializing in biopharmaceutical advancements and drug pipelines.
Get Latigo Biotherapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Latigo Biotherapeutics in Xcout Intel
- 24 named people with titles, LinkedIn and board committees
- 7 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access